Suramin for the Treatment of Autism Trial: KZ101 in a Male Pediatric Population With Autism Spectrum Disorder (ASD)
NCT06866275
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
Suramin has been found to correct the symptoms, metabolism, and brain synaptic abnormalities in two classical genetic and environmental mouse models of autism. A preliminary clinical trial (SAT-1) examined the safety and activity of a single low-dose of suramin in children with ASD and concluded suramin showed promise as a novel approach to treatment of ASD.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Autism Spectrum Disorder (ASD)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 5 to 14 years
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Children's Hospital of Orange County
- Last updated on ClinicalTrials.gov
- July 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Children's Hospital Orange County, Thompson Autism and Neurodevelopmental Center · Orange, CA
Maryland · 1
- Kennedy Krieger Institute · Baltimore, MD
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.